Zeluvalimab

泽瓦利单抗

Report date: 2023/11/08 20:09:12

Base Information

Drug NameZeluvalimab
Drug Alias NameAMG-404
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionAnti-PD-1
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsSolid tumoursProstatic Neoplasms, Castration-ResistantSmall Cell Lung Carcinoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[21] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesAmgen Inc
Inactive CompaniesAmgen Biotechnology Consultation (Shanghai) Co Ltd
Active IndicationsSolid tumoursSmall Cell Lung CarcinomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsProstatic Neoplasms, Castration-Resistant

Other Information

ATC CodeN/A
Related LinksN/A